In addition to treating diabetes, other PPAR-γ agonists in the list are currently under the phase I/II clinical trial for the treatment of hyperuricemia (arhalofenate), non-alcoholic steatohepatitis (lanifibranor and T3D-959), systemic sclerosis (lanifibranor), Alzheimer’s disease (T3D-959), and multiple sclerosis (VCE-004.8, [25–28]). The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.